Latest studies
- Ongoing, recruitingTherapeutic exploratory (Phase II)
J3E-MC-EZDB: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3540378 in Adults with Worsening Chronic Heart Failure with Preserved Ejection Fraction (HFpEF)
This study is looking into a new medication called LY3540378 for people with a type of heart failure where the heart struggles to relax properly. Researchers want to see if this new medicine can help improve how the heart works and if it's safe to use.
Heart Failure with Preserved Ejection Fraction, Heart FailureCzechia - Ongoing, recruitingPhase II and Phase III (Integrated)
A Phase 2/3, adaptive, randomized, open-label, clinical study to evaluate neoadjuvant and adjuvant V940 (mRNA-4157) in combination with pembrolizumab (MK-3475) versus standard of care, and pembrolizumab monotherapy in participants with resectable locally advanced cutaneous squamous cell carcinoma (LA cSCC) (INTerpath-007).
This study is looking at a new treatment for a type of skin cancer called cutaneous squamous cell carcinoma (cSCC). It combines a new vaccine (mRNA-4157) with an existing drug (pembrolizumab) to see if it works better than standard care for people whose cancer can be removed by surgery.
Czechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Open-Label, Multicenter, Phase II Study of Multiple Doses of RO7247669 in Participants with Previously Untreated Unresectable or Metastatic Melanoma
This study is testing a new medicine called RO7247669 for advanced skin cancer (melanoma) that has spread or can't be removed by surgery. It's an early-stage trial looking at how safe the medicine is and if it can help slow down or stop the cancer from growing.
Unresectable or Metastatic MelanomaCzechia - RecruitingPHASE2, PHASE3
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
This study looks at a new drug, ficerafusp alfa, combined with pembrolizumab (Keytruda®) for people with advanced head and neck cancer. It compares this combination against pembrolizumab alone to see if it works better and is safe.
Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaCzechia - Ongoing, recruitingPhase II and Phase III (Integrated)
A two-part randomized, double-blind, placebo-controlled multicenter dose ranging and confirmatory study to assess the safety and efficacy of VAY736 in autoimmune hepatitis patients with incomplete response to or intolerance of standard therapy (AMBER)
This study is looking into a new treatment, VAY736, for adults with a liver condition called autoimmune hepatitis. It aims to see if VAY736 is safe and helps improve liver blood tests for people whose current treatments aren't working well or cause side effects.
Autoimmune hepatitisCzechia - Ongoing, recruitingPhase II and Phase III (Integrated)
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
This study is looking into a new medicine, efgartigimod, for people with bullous pemphigoid (BP). It compares efgartigimod to a dummy drug (placebo) to see if it can help patients achieve clear skin without needing steroid tablets for a long time.
Bullous Pemphigoid (BP)Czechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE)
This study is testing a new medicine called semaglutide for people with early Alzheimer's disease. Researchers want to see if it can help improve memory and thinking, and how safe it is to use.
Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s typeCzechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A multi-centre, single arm, open-label extension study to evaluate the long-term safety of GSK3511294 (Depemokimab) in adult and adolescent participants with severe asthma with an eosinophilic phenotype from studies 206713 or 213744
This study looks at the long-term safety of a new medicine, GSK3511294 (Depemokimab), for adults and teenagers with severe asthma. Participants have already taken part in earlier studies of this medicine. We'll check for side effects and how their asthma is doing over a year.
Severe asthma with an eosinophilic phenotypeCzechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A parallel-group, prevention, Phase III, modified double-blind, 2-arm, study to investigate the immunogenicity and describe the safety of a quadrivalent meningococcal conjugate vaccine (MenACYW conjugate vaccine) compared with Nimenrix® when administered in a 1+1 schedule in healthy infants and toddlers at 6 and 12 months of age
This study is looking at a new vaccine to protect babies and young children from meningococcal disease. We are comparing how well this new vaccine works and its safety compared to a current vaccine, Nimenrix, in healthy infants and toddlers in the UK.
Healthy volunteers (Meningococcal infection)Czechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102)
This study is for people with advanced stomach or gut cancer that has a specific genetic marker called FGFR2b. It tests a new drug, bemarituzumab, combined with usual treatments (chemotherapy and nivolumab) to see if it works better than usual treatments alone.
Gastric and Gastroesophageal Junction Cancer With FGFR2b OverexpressionCzechia - Active not recruitingPHASE3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
This study looks at a new drug, epcoritamab, combined with standard medicines (R2) for adults with follicular lymphoma that has come back or not responded to previous treatments. It aims to see how safe and effective this new combination is.
Follicular Lymphoma (FL)Czechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study With a Randomized Withdrawal and Retreatment Period to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis
This study is testing a new medicine, ZASOCITINIB (also called TAK-279), for people with moderate to severe plaque psoriasis. It compares the new medicine to existing treatments like Otezla and a dummy pill (placebo) to see how well it works and if it's safe.
Moderate to Severe Plaque PsoriasisCzechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A participant - and investigator-blinded, randomized, placebo-controlled, multicenter, platform study to investigate efficacy, safety, and tolerability of various single treatments in patients with idiopathic pulmonary fibrosis
This study is looking into new treatments for Idiopathic Pulmonary Fibrosis (IPF). It compares a new medicine, LTP001, with a dummy pill (placebo) to see if it can slow down the lung disease and improve how people feel, checking for safety and side effects along the way.
Idiopathic pulmonary fibrosisCzechia - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A randomized, open-label, single dose, cross-over study to evaluate the drug-drug interaction between Proscar 5 mg, film-coated tablets and Cialis 5 mg film-coated tablets when co-administered versus the administration of each product alone in healthy volunteers under fasting conditions. Study no. FIN-TAD-DDI-03-24
This study looks at how two common medicines, Proscar and Cialis, work when taken together compared to taking them separately. It helps understand if they affect each other in healthy men. It's a very early stage study.
healthy male subjectsCzechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
IMPAHCT-FUL: A Long-Term Extension, Multi-Center Safety Study of AV-101 in Subjects With Pulmonary Arterial Hypertension (PAH) Who Have Completed Study AV-101-002
This study looks at the long-term safety of a new medicine, AV-101, for people with pulmonary arterial hypertension (PAH). It's for those who have already tried AV-101 in a previous study and aims to learn more about how well it's tolerated over time.
Pulmonary Arterial Hypertension (PAH)Czechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer
This study looks at whether a drug called Nivolumab can help prevent cancer from coming back in people who have had surgery for oesophageal or stomach cancer. It compares Nivolumab to a dummy drug to see if it improves the time patients live without their cancer returning.
Subjects with resected adenocarcinoma or squamous cell carcinoma esophageal or gastroesophageal junction cancerCzechia - Active not recruitingPHASE3
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
This study is looking at how well two new drugs, enfortumab vedotin and pembrolizumab, work together to treat advanced bladder cancer that has spread. It compares them to standard chemotherapy treatments to see if they are a better option.
Urothelial CancerCzechia - RecruitingPHASE3
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
This study offers ongoing treatment with pelacarsen for people who have finished a previous trial for heart disease. It aims to check the long-term safety of the medicine, which helps lower a type of cholesterol called Lp(a).
Cardiovascular Disease and Lipoprotein(a)Czechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
CA209-8HW A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer
This study looks at new drug combinations for advanced bowel cancer that has specific genetic changes (MSI-H or dMMR). It compares them to standard chemotherapy to see which is better at stopping the cancer from growing.
Microsatellite Instability High (MSI-H) or Mismatch Repair DeficientMetastatic Colorectal Cancer (dMMR)Czechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
This study looks at a new medicine called Evolocumab to see if it can lower the chance of serious heart problems like heart attacks or strokes in people at high risk who haven't had them before. It compares Evolocumab to a dummy medicine.
Adults at high risk of cardiovascular events without prior MI or stroke.Czechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
This study is looking at new treatments for advanced kidney cancer. It compares a combination of two drugs, nivolumab and cabozantinib, against a standard treatment, sunitinib, to see which works better and is safer for people who haven't had treatment before.
Advanced or Metastatic Renal Cell CarcinomaCzechia - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer
This study is testing a new medicine called tisotumab vedotin for advanced cervical cancer that has come back or spread. It looks at how safe the medicine is by itself and when given with other common cancer drugs, and how well it works to shrink tumours.
Recurrent or stage IVB cervical cancerCzechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis.
This study is testing a new medicine, amlitelimab, for moderate-to-severe eczema in people aged 12 and over. It compares amlitelimab to a dummy medicine (placebo) to see if it improves eczema symptoms like itching and skin clearing.
Dermatitis atopicCzechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, randomized, double-blind clinical study of pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy as first-line treatment in participants with HER2 negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (KEYNOTE-859)
This study is testing a new medicine, pembrolizumab (Keytruda), alongside standard chemotherapy for advanced stomach or food pipe cancer. It aims to see if this combination helps people live longer compared to chemotherapy alone, especially for cancers that don’t have too much of a protein called HER2.
Gastric and gastric esophageal junction (GEJ) adenocarcinomaCzechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, Multicenter Induction Study with an Active Treatment Extension to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Patients with Moderate to Severe Ulcerative Colitis
This study is testing a new drug, called Vixarelimab, for adults with moderate to severe ulcerative colitis. It aims to see how well it works to reduce symptoms and improve the gut, as well as checking its safety and how the body handles it.
Ulcerative Colitis (UC)Czechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) with Orencia® administered by the intravenous route as an add-on to methotrexate in the treatment of patients with moderate to severe rheumatoid arthritis
This study is comparing a new version of a rheumatoid arthritis medicine, called DRL_AB, with an existing one, Orencia. It aims to see if the new medicine works as well, is safe, and causes a similar immune response in people with moderate to severe rheumatoid arthritis.
Rheumatoid ArthritisCzechia - Active not recruitingPHASE3
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
This study is looking at the long-term safety of a treatment called secukinumab for people with Polymyalgia Rheumatica (PMR). It's for those who have already been in a previous study for secukinumab and had their PMR symptoms come back after stopping treatment.
Polymyalgia RheumaticaCzechia - Active not recruitingPHASE3
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
This study looks at a drug called abemaciclib, given with standard hormone therapy after surgery for a type of breast cancer. We want to see if it's safe and helps stop the cancer coming back in people with certain high-risk breast cancers.
Breast CancerCzechia - Active not recruitingPHASE3
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
This study looks at new drug combinations for advanced lung cancer. It compares a new drug (Datopotamab Deruxtecan) with an existing treatment (Pembrolizumab) and chemotherapy, to see if the new combinations are safer and work better.
Metastatic Non Small Cell Lung CancerCzechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma
This study is looking at a new way to treat follicular lymphoma, a type of cancer. It compares a drug called Ibrutinib with a standard treatment, Rituximab. The aim is to see if adding Ibrutinib helps people live longer without their cancer getting worse.
Follicular LymphomaCzechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A 14-Week Phase 2b, RandomizEd, Double-BLind, Dose-Ranging Study to Determine the PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts with Moderate to Severe Ulcerative Colitis or Crohn’s Disease (RELIEVE UCCD)
This study is testing a new medicine called TEV-48574 for adults with moderate to severe Crohn's disease or ulcerative colitis. It aims to see how well it works, if it's safe, and how the body handles it, comparing it to a dummy medicine.
Crohn’s disease, Ulcerative colitisCzechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction
This study is testing a new medicine, Tovinontrine, for people with a type of heart failure where the heart struggles to pump blood effectively. It aims to see if different doses are safe and if the medicine helps improve heart health over 12 weeks.
Heart failure (HF) with reduced ejection fraction (HFrEF)Czechia - RecruitingPHASE3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
This study looks at new ways to treat multiple myeloma. Researchers are testing a drug called elranatamab, alone and with daratumumab, against a standard treatment. The aim is to find better and safer treatments for people who have tried other medicines.
Multiple MyelomaCzechia - Active not recruitingPHASE2, PHASE3
International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma
This study looks at new ways to treat medulloblastoma, a type of brain tumour, in children and young people. It aims to find the best treatments based on the tumour's specific characteristics, hoping to improve the chances of recovery with fewer side effects.
Brain TumorsCzechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
An adaptive, randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of RL-007 in the treatment of cognitive impairment associated with schizophrenia (CIAS)
This study is looking into a new medication called RL-007 to help people with schizophrenia improve their thinking, learning, and memory skills. It's a key step to see if RL-007 is safe and effective.
Cognitive disorder, SchizophreniaCzechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11/GOG-3047)
This study is testing a new treatment combination for locally advanced cervical cancer. It compares standard chemotherapy and radiation with the same treatment plus a new drug, pembrolizumab (Keytruda), to see if it helps patients live longer and stops the cancer from growing.
Locally Advanced Cervical CancerCzechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial to investigate the efficacy and safety of daxdilimab subcutaneous injection in reducing disease activity in adult participants with moderate-to-severe primary discoid lupus erythematosus.
This study is looking into a new medication called daxdilimab for adults with a type of lupus called discoid lupus erythematosus. Researchers want to see if this medicine can improve skin symptoms and if it's safe to use compared to a dummy treatment.
Primary Discoid Lupus ErythematosusCzechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
Effects of NNC0194-0499 alone and in combination with semaglutide, of semaglutide alone, and of cagrilintide alone and in combination with semaglutide on liver damage and alcohol use in people with alcohol-related liver disease
This study is testing different new medicines, alone or in combination, to see if they can help improve liver damage and reduce alcohol use in people with liver problems caused by alcohol. One of the medicines is similar to a type already used for diabetes.
alcohol-related liver diseaseCzechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejection Fraction
This study is testing a new medicine, Tovinontrine, for people with a type of chronic heart failure. It aims to see if the medicine is safe and if it can improve how the heart works according to blood tests, compared to a dummy pill.
chronic heart failureCzechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
This study is looking at a new medicine called Efavaleukin Alfa for people with moderate to severe Ulcerative Colitis. We want to see if it's safe and helps people feel better and get their condition under control within 12 weeks.
Ulcerative Colitis (UC)Czechia - Active not recruitingPHASE2, PHASE3
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
This study looks at a new drug, efgartigimod PH20 SC, for adults with active idiopathic inflammatory myopathy (IIM), a condition causing muscle weakness and inflammation. It compares the drug to a dummy treatment to see if it helps improve muscle strength and overall well-being.
Active Idiopathic Inflammatory MyopathyMyositisDermatomyositisPolymyositisCzechia - Ongoing, recruitingTherapeutic use (Phase IV)
Adjustable brodalumab dosage regimen compared with standard brodalumab treatment for 52 weeks in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight; ADJUST - Phase 4 – efficacy, A randomised, double-blind, controlled, parallel group, multi-centre trial
This study compares a flexible dose of Brodalumab, a psoriasis treatment, with its usual dose for people with moderate to severe plaque psoriasis who weigh 120 kg or more. It aims to see if the adjustable dose works better at clearing skin.
Moderate-to-severe plaque psoriasis and a body weight ≥120 kg.Czechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An open label, single arm, extension trial to examine long-term safety of Iclepertin once daily in patients with schizophrenia who have completed previous Iclepertin Phase III trials.(CONNEX-X)
This study is looking at the long-term safety of a new medicine called Iclepertin for people with schizophrenia. It's for those who have already taken part in earlier studies of this medicine. We want to see how safe it is over a longer period.
SchizophreniaCzechia - Active not recruitingPHASE3
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
This study is looking into a new medication called Pelacarsen. It aims to see if this medicine can help people with heart disease who have high levels of a specific type of 'bad' cholesterol (Lipoprotein(a)) reduce their risk of future heart problems.
Cardiovascular Disease and Lipoprotein(a)Czechia - Active not recruitingPHASE3
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
This study looks at a new drug, Sacituzumab Govitecan, for advanced breast cancer. It compares it to standard treatments to see if it can slow cancer growth or spread, helping people live longer and healthier lives.
Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast CancerCzechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
58-week Open-Label Trial of Tavapadon in Parkinson’s Disease (Tempo-4 Trial)
This study is looking at a new medication called Tavapadon for people with Parkinson's disease. Researchers want to see if it's safe and how well it helps with symptoms over 58 weeks. It's a Phase 3 trial, meaning it's a big step towards potentially becoming a new treatment.
Parkinson's diseaseCzechia - Active not recruitingPHASE2
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
This study looks at a new drug, pembrolizumab, combined with standard chemotherapy for children and young adults (3-25 years old) with newly diagnosed classical Hodgkin Lymphoma. It specifically focuses on those who aren't responding quickly to initial treatment.
Hodgkin LymphomaCzechia - Active not recruitingNA
Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)
This study is looking into a new way to help people with heart failure by stimulating a nerve called the vagal nerve. It involves a small implanted device and aims to improve heart health and quality of life.
Heart FailureCongestive Heart FailureCzechia - Active not recruitingPHASE2
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
This study is looking at new treatments for a specific type of ovarian cancer that has come back or won't go away. We want to see if these treatments are safe and effective for patients whose cancer has certain genetic features.
Ovarian CancerCzechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Naive Subjects with Active Psoriatic Arthritis II (INSPIRE 2)
This study is testing a new medicine, Ilumetri, for adults with active psoriatic arthritis who haven’t used similar medicines before. Researchers want to see if it helps reduce symptoms like joint pain and swelling, and if it’s safe to use. Half the people will get the medicine, and half will get a dummy injection.
Psoriatic ArthritisCzechia